Antitumor effect of OK-432-derived DNA: One of the active constituents of OK-432, a streptococcal immunotherapeutic agent

Journal of Immunotherapy

Volumn 29, Issue 2, 2006, Pages 143-150

  Oshikawa, Tetsuya ^a   Okamoto, Masato ^a   Tano, Tomoyuki ^a   Sasai, Akiko ^a   Kan, Shin ^a   Moriya, Yoichiro ^b   Ryoma, Yoshiki ^b   Saito, Motoo ^b   Akira, Shizuo ^c   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Antitumor immunotherapy; CpG DNA; Streptococcal preparation OK 432; Toll like receptor 9

Indexed keywords

BACTERIAL DNA; CHROMIUM 51; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; PICIBANIL; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROLEUKEMIA CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SPLEEN CELL; STREPTOCOCCUS; TREATMENT OUTCOME; TUMOR; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CPG ISLANDS; CYTOTOXICITY, IMMUNOLOGIC; DNA METHYLATION; DNA, BACTERIAL; HUMANS; IMMUNOTHERAPY; MICE; MUTATION; NEOPLASMS, EXPERIMENTAL; PICIBANIL; STREPTOCOCCUS PYOGENES; TH1 CELLS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9;

EID: 33646784013     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000189028.18288.6f     Document Type: Article

References (37)

1. Okamoto H, Shoin S, Koshimura S, et al. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol. 1967;11:323-336.
2. Kikkawa F, Kawai M, Oguchi H, et al. Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. Eur J Cancer. 1993;29:1542-1546.
3. Maehara Y, Okuyama T, Kakeji Y, et al. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg. 1994;168:36-40.
4. Sato M, Harada K, Yoshida H, et al. Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: association of the therapeutic effect with differentiation and apoptosis in the cancer cells. Apoptosis. 1997;2:227-238.
5. Okamoto M, Oshikawa T, Tano T, et al. Involvement of Toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst. 2003;95: 316-326.
6. Oshimi K, Kano S, Takaku F, et al. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst. 1980;65:1265-1269.
7. Misaki T, Watanabe Y, Iida Y, et al. Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy. Cancer Immunol Immunother. 1992;35:92-96.
8. Fujimoto T, Duda RB, Azilvasi A, et al. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 1997;158:5619-5626.
9. Okamoto T, Harada M, Tamada K, et al. Local injection of OK-432 can augment the Th1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential. Int J Cancer. 1997;70:598-605.
10. Nakahara S, Tsunoda T, Baba T, et al. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 2003;63:4112-4118.
11. Itoh T, Ueda Y, Okugawa K, et al. Streptococcal preparation OK-432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother. 2003;52:207-214.
12. Kuroki H, Morisaki T, Matsumoto K, et al. Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 2003;52:561-568.
13. Okamoto M, Furuichi S, Nishioka Y, et al. Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 2004;64:5461-5470.
14. Ahmed SU, Okamoto M, Oshikawa T, et al. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of Toll-like receptor 4. J Immunother. 2004;27:432-441.
15. Okamoto M, Kaji R, Kasetani H, et al. Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432. J Immunother. 1993;13:232-242.
16. Takada H, Kawabata Y, Arakaki R, et al. Molecular and structural requirements of a lipoteichoic acid from Enterococcus hirae ATCC 9790 for cytokine-inducing, antitumor, and antigenic activities. Infect Immun. 1995;63:57-65.
17. Okamoto M, Gohda H, Ohe G, et al. Cytokine-inducing activity and anti-tumor effect of liposome-incorporated interferon-γ-inducing molecule derived from OK-432, a streptococcal preparation. J Immunother. 2000;23:94-103.
18. Okamoto M, Ohe G, Oshikawa T, et al. Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent. Immunopharmacology. 2000;49:363-376.
19. Okamoto M, Ohe G, Oshikawa T, et al. Enhancement of anticancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus. Cancer Immunol Immunother. 2001;50:408-416.
20. Okamoto M, Oshikawa T, Ohe G, et al. Comparison of cytokine-inducing activity in a lipoteichoic acid-related molecule isolated from a penicillin-killed group A Streptococcus and untreated bacteria. Int Immunopharmacol. 2001;1:1957-1968.
21. Okamoto M, Ohe G, Furuichi S, et al. Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells. Anticancer Res. 2002;22:3229-3240.
22. Oshikawa T, Okamoto M, Ohe G, et al. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-γ-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction. Int Immunopharmacol. 2003;3:643-655.
23. Okamoto M, Oshikawa T, Ohe G, et al. Severe impairment of anticancer effect of lipoteichoic acid-related molecule isolated from a penicillin-killed Streptococcus pyogenes in toll-like receptor 4-deficient mice. Int Immunopharmacol. 2001;1:1789-1795.
24. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999;189:1777-1782.
25. Rock FL, Hardiman G, Timans JC, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA. 1998;95:588-593.
26. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406:782-787.
27. Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999;274:10689-10692.
28. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-760.
29. Lipford GB, Sparwasser T, Zimmermann S, et al. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol. 2000; 165:1228-1235.
30. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
31. Doerfler W. DNA methylation and gene activity. Annu Rev Biochem. 1983;52:93-124.
32. Anderson LC, Nilsson K, Gahmberg CG. K-562, a human erythroleukemic cell line. InI J Cancer. 1979;23:143-147.
33. Klein E, Klein G, Nadkarni JS, et al. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 1968;28:1300-1310.
34. Bertram JS, Janik P. Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett. 1980;11:63-73.
35. Hoshino K, Takeuchi O, Kawai T, et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162:3749-3752.
36. Timonen T, Saksela E. A simplified isotope release assay for cell-mediated cytotoxicity against anchorage-dependent target cells. J Immunol Methods. 1977;18:123-132.
37. Chatellier S, Kotb M. Preferential stimulation of human lymphocytes by oligodeoxynucleotides that copy DNA CpG motif present in virulent genes of group A streptococci. Eur J Immunol. 2000; 30:993-1001.